New study aims to give ileostomy patients a voice in Crohn's trials
NCT ID NCT06670638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study involves about 50 adults with Crohn's disease who have a permanent ileostomy (a surgically created opening in the belly to pass waste). The goal is to create new tools—a patient questionnaire and an endoscopic scoring system—to accurately measure disease activity in this group. Currently, these patients are often left out of clinical trials because there are no good ways to track their condition. By developing these tools, researchers hope to include them in future studies for new treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHNS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic Foundation
RECRUITINGCleveland, Ohio, 44195, United States
-
LHSC - University Campus
RECRUITINGLondon, Ontario, L6S 0E2, Canada
-
Mayo Clinic- Rochester
RECRUITINGRochester, Minnesota, 55905, United States
-
McMaster University Medical Centre
RECRUITINGHamilton, Ontario, L6S 0E2, Canada
-
Washington University in St Louis School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple hospital checklist could flag hidden malnutrition in kids with IBD
- Green gut check: can ultrasound slash the carbon cost of IBD testing?
- Real-World surgery study aims to improve fistula care
- New Dye-Free colonoscopy could make cancer screening easier for IBD patients
- Hidden mineral shortage: new study targets magnesium in gut patients
- Real-World study tracks how IBD patients choose between IV and injectable vedolizumab